Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.44 |
| ▸ | HPGD | P15428 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 3/20 | 0.43 |
| ▸ | ACHE | P22303 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4824189 | 1.00 | ALDH1A1 (0.44) | ALDH1A1L3MBTL1HPGDKDM4EMAPT | |
| SCHEMBL4825621 | 0.81 | ALDH1A1 (0.44) | ALDH1A1L3MBTL1HPGDKDM4EHTT | |
| SCHEMBL4824407 | 0.81 | LMNA (0.39) | ALDH1A1L3MBTL1MAPTHTTMEN1 | |
| SCHEMBL4824398 | 0.81 | LMNA (0.39) | ALDH1A1L3MBTL1MAPTHTTMEN1 | |
| SCHEMBL7601817 | 0.77 | MEN1 (0.64) | ALDH1A1L3MBTL1HPGDKDM4EMAPT | |
| SCHEMBL4819605 | 0.77 | ALDH1A1 (0.53) | ALDH1A1L3MBTL1HPGDMAPTHTT | |
| SCHEMBL4819612 | 0.77 | ALDH1A1 (0.53) | ALDH1A1L3MBTL1HPGDMAPTHTT | |
| SCHEMBL4823281 | 0.77 | MAPT (0.49) | ALDH1A1L3MBTL1KDM4EMAPTHTT | |
| SCHEMBL4823274 | 0.77 | MAPT (0.49) | ALDH1A1L3MBTL1KDM4EMAPTHTT | |
| SCHEMBL29957009 | 0.76 | MAPT (0.50) | ALDH1A1L3MBTL1HPGDKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465738-B2 | Compounds useful as promoters of SMN2 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-12-16 | — | — | US | disclosed |
| US-7465738-B2 | Compounds useful as promoters of SMN2 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-12-16 | — | — | US | disclosed |
| US-7465738-B2 | Compounds useful as promoters of SMN2 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-12-16 | — | — | US | disclosed |
| US-20050065173-A1 | Compounds useful as promoters of SMN2 | VERTEX PHARMACEUTICALS INCORPORATED | 2005-03-24 | — | — | US | disclosed |
| WO-2004113305-A2 | DIAMINO SUBSTITUTED QUINAZOLINE DERIVATIVES AS PROMOTERS OF SMN2 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-12-29 | — | — | WO | disclosed |
| WO-2004113305-A2 | DIAMINO SUBSTITUTED QUINAZOLINE DERIVATIVES AS PROMOTERS OF SMN2 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065173-A1 | Compounds useful as promoters of SMN2 | SMN1; SMN2, NSUN2, MECP2 | ALDH1A1 1813/4885L3MBTL1 893/4885HPGD 2153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.